Systematic review found nabiximols and CBD more promising than THC-based drugs for treating cannabis use disorder
A systematic review of 8 RCTs found that endocannabinoid modulators (nabiximols, CBD, PF-04457845) showed broader efficacy for cannabis use disorder than cannabinoid receptor agonists (dronabinol, nabilone).
Quick Facts
What This Study Found
Dronabinol reduced withdrawal symptoms but had limited broader efficacy. Nabilone failed to demonstrate efficacy. In contrast, nabiximols, CBD, and PF-04457845 reduced cannabis use and improved abstinence across multiple CUD outcomes. All medications were well-tolerated.
Key Numbers
8 RCTs, 667 participants. Dronabinol: reduced withdrawal only. Nabilone: no efficacy. Nabiximols: reduced use and improved abstinence. CBD: reduced use and improved abstinence. PF-04457845: reduced use and improved abstinence.
How They Did This
Systematic review of 8 randomized controlled trials evaluating medical cannabinoids for CUD (667 total participants). Outcomes assessed: cannabis use, abstinence, withdrawal, craving, treatment retention, and adverse events.
Why This Research Matters
There are no approved medications for cannabis use disorder. This review identifies endocannabinoid modulation (rather than direct receptor agonism) as the more promising pharmacological strategy.
The Bigger Picture
The distinction between direct agonists (limited efficacy) and endocannabinoid modulators (broader efficacy) mirrors developments in other addiction fields and could shape the future of CUD pharmacotherapy.
What This Study Doesn't Tell Us
Only 8 trials available with 667 total participants. Small individual study sizes. Different doses, durations, and outcome measures across trials. Short follow-up periods.
Questions This Raises
- ?What is the optimal dose and duration for nabiximols or CBD in CUD treatment?
- ?Would combining medications improve outcomes?
- ?Can these medications help people reduce use if complete abstinence is not the goal?
Trust & Context
- Key Stat:
- Endocannabinoid modulators covered almost all aspects of CUD treatment
- Evidence Grade:
- Moderate: systematic review of RCTs, but limited by small number and size of included trials.
- Study Age:
- Published in 2022.
- Original Title:
- Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials.
- Published In:
- Frontiers in psychiatry, 13, 867878 (2022)
- Authors:
- Vuilleumier, Caroline, Scherbaum, Norbert(7), Bonnet, Udo(8), Roser, Patrik
- Database ID:
- RTHC-04283
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Is there an approved medication for cannabis use disorder?
No. As of this review, there are no approved pharmacological treatments for CUD. This review identifies endocannabinoid modulators as the most promising direction.
What is the difference between agonists and modulators?
Agonists like dronabinol directly activate cannabinoid receptors (similar to THC). Modulators like nabiximols and CBD influence the endocannabinoid system more broadly, which appears to produce better treatment outcomes.
Was CBD effective for cannabis dependence?
Yes. CBD reduced cannabis use and improved abstinence in the included trials, suggesting it may help people reduce or stop using cannabis.
Read More on RethinkTHC
- 30-days-without-weed
- 420-sober-survival-guide
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- CBT-cannabis-recovery
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-relapse-cycle-pattern
- cannabis-use-disorder-test
- cold-turkey-vs-taper-quit-weed
- creativity-without-weed-quitting-artist-musician
- cross-addiction-quit-weed-start-drinking
- dating-sober-after-quitting-weed
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- help-someone-quit-weed
- hobbies-after-quitting-weed
- how-to-quit-weed
- identity-after-quitting-weed
- is-weed-addictive
- is-weed-addictive-science
- journaling-weed-withdrawal
- leaving-stoner-culture-identity
- marijuana-anonymous-SMART-recovery-compare
- meditation-mindfulness-weed-withdrawal
- money-saved-quitting-weed-calculator
- one-year-sober-weed
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-and-alcohol
- quitting-weed-creativity
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-face-changes-skin
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- quitting-weed-weight-loss-gain
- rehab-for-weed-addiction-necessary
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- should-i-quit-weed
- signs-of-cannabis-use-disorder
- sober-music-festival-concert-without-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-04283APA
Vuilleumier, Caroline; Scherbaum, Norbert; Bonnet, Udo; Roser, Patrik. (2022). Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials.. Frontiers in psychiatry, 13, 867878. https://doi.org/10.3389/fpsyt.2022.867878
MLA
Vuilleumier, Caroline, et al. "Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials.." Frontiers in psychiatry, 2022. https://doi.org/10.3389/fpsyt.2022.867878
RethinkTHC
RethinkTHC Research Database. "Cannabinoids in the Treatment of Cannabis Use Disorder: Syst..." RTHC-04283. Retrieved from https://rethinkthc.com/research/vuilleumier-2022-cannabinoids-in-the-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.